BASS XIX Tutorials and Keynote Address presentations:

M-1Russell ReeveModel-Based Drug Development
M-2Jeffrey MorrisModeling High-Dimension Functioning and Image Data
M-3 Ying Yuan Bayesian Optimal Interval Design for Phase I Clinical Trial
M-4Roy SaboA Bayesian Adaptive Allocation Method for Clinical Trial and Dual Objectives
M-5Cory HeilmannUse of Bayesian Evidence Synthesis Techniques Across Phases of Drug Development
M-6Doug FariesComparative Effectiveness Analysis from Observational Data
M-7Joe CappelleriNetwork Meta-Analysis for Comparative Effectiveness Research
M-8 Susan Duke Graphs are Statistical Methods Too! The Case for Graphics in Safety and Benefit-Risk Analysis
Keynote AddressChristy Chuang-SteinCareer in Pharmaceutical Industry: Exciting, Challenging and Rewarding
T-1Melvin MunsakaStatistical Analysis of Safety Data – A Survey of Some Analysis Methods
T-2Frank RockholdEnhancing the Way We Quantify and Communicate Benefit to Risk in the Pre and Post Approval Arena
T-3Jesse BerlinOpportunities and Challenges for Using Networks of Observational Healthcare Data for Medical Product Safety Surveillance
T-4Zhenzhen XuPropensity Scoring Matching in Cluster Randomized Trials
T-5Xiaolong LuoA Multiple Comparison Procedure for Hypotheses with Gatekeeping Structures
T-6Colleen Twomey21st Century Drug Development: The Road to Consistency and Transparency
W-1Aloka ChakravartyQuantitative Safety Evaluation at CDER
W-2Estelle Russek-CohenSafety Throughout the Life Cycle of Vaccines
W-3 Mark Levenson Quantitative Safety Assessment During the Post-Marketing Phase: Examples at FDA/CDER
W-4Christy Chuang-SteinSafety Assessment of Pharmaceutical Products